Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more
Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Liabilities
Latest total liabilities as of September 2025: CN¥877.24 Million CNY
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has total liabilities worth CN¥877.24 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Liabilities Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SCHOTT Pharma AG & Co. KGaA
XETRA:1SXP
|
Germany | €650.00 Million |
|
Lee and Man Paper Manufacturing Limited
F:LMP
|
Germany | €26.93 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥797.08 Million |
|
Fukuyama Transporting Co. Ltd
F:FUY
|
Germany | €225.09 Billion |
|
Beijing Chieftain Control Engineering Technology Co Ltd
SHE:300430
|
China | CN¥1.49 Billion |
|
Anterix Inc
NASDAQ:ATEX
|
USA | $181.05 Million |
|
Revenio Group Corporation
HE:REG1V
|
Finland | €30.80 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cheng Du Sheng Nuo Biotec Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥729.58 Million | +67.48% |
| 2023-12-31 | CN¥435.63 Million | +54.88% |
| 2022-12-31 | CN¥281.27 Million | +64.03% |
| 2021-12-31 | CN¥171.48 Million | +10.34% |
| 2020-12-31 | CN¥155.41 Million | +9.09% |
| 2019-12-31 | CN¥142.46 Million | -5.59% |
| 2018-12-31 | CN¥150.90 Million | +41.74% |
| 2017-12-31 | CN¥106.46 Million | -- |